About BPG Bio, Inc
#biopharma #therapeutics #mitochondrial #oncology #neurology #raredisease #drugdiscovery
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Waltham, Massachusetts
- Founded
- 2006
- Company type
- Privately Held
- Company profile name
- BPGbio, Inc.
BPGbio is a clinical-stage biopharmaceutical company focused on developing mitochondrial-targeted therapies for patients. The company’s approach is grounded in advancing therapeutics that restore cellular energy regulation and address mitochondrial dysfunction, a central driver of disease across multiple high-burden indications.
BPGbio’s lead clinical candidate, BPM31510, is a potential first-in-class mitochondrial metabolic modulator currently in clinical development for Primary CoQ10 Deficiency (PCQD) and Glioblastoma. The asset has also completed a phase I trial in Epidermolysis Bullosa (EB). The company is currently exploring the potential of BPM31510 in small cell carcinoma (SCC), pancreatic cancers, and sarcopenia.
Specialties
- Biotechnology
- rare diseases
- Oncology
- Neurology
- mitochondrial
- Bayesian AI
- BPM31510
- Primary CoQ10 Deficiency
- and Glioblastoma
Company locations
300 3rd Ave, Waltham, Massachusetts 02451, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
Business areas
- Health Care
- Biopharma
- Biotechnology
- Artificial Intelligence (AI)
- Pharmaceutical
On LinkedIn
- Followers
- 8,902
- People linked to this company
- 70
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Funding raised
480,000,000 USD
Total reported by Crunchbase, in US dollars. This is funding raised, not company revenue or valuation.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.